Edited by Jacomine Krijnse-Locker SAMHD1 inhibits Hepatitis B virus (HBV) replication by reducing the intracellular dNTP levels. However, how SAMHD1 phosphorylation is regulated to abrogate its restriction of HBV replication in hepatoma cells is poorly understood. Here, we show that HBV replication and SAMHD1 phosphorylation levels are significantly reduced by knocking down cyclin-dependent kinase (CDK) 2 expression or in the presence of a CDK2 inhibitor. SAMHD1 binds to CDK2 in hepatocarcinoma cells, and this interaction does not require the HBV core protein. Furthermore, cyclin E2 participates in regulating viral replication through the CDK2/SAMHD1 phosphorylation pathway in an HBV infection system. Collectively, our results provide evidence that CDK2 has a greater role in regulating SAMHD1 phosphorylation and HBV replication than CDK1 or CDK6.
SAMHD1 inhibits Hepatitis B virus (HBV) replication by reducing the intracellular dNTP levels. However, how SAMHD1 phosphorylation is regulated to abrogate its restriction of HBV replication in hepatoma cells is poorly understood. Here, we show that HBV replication and SAMHD1 phosphorylation levels are significantly reduced by knocking down cyclin-dependent kinase (CDK) 2 expression or in the presence of a CDK2 inhibitor. SAMHD1 binds to CDK2 in hepatocarcinoma cells, and this interaction does not require the HBV core protein. Furthermore, cyclin E2 participates in regulating viral replication through the CDK2/SAMHD1 phosphorylation pathway in an HBV infection system. Collectively, our results provide evidence that CDK2 has a greater role in regulating SAMHD1 phosphorylation and HBV replication than CDK1 or CDK6.
Keywords: CDK2; hepatitis B virus; phosphorylation; SAMHD1 Cellular innate immunity is the first line of host defense against a virus infection. Innate immune signaling pathways are induced following virus infection and cause induction of interferon (IFN) and IFN-stimulated genes (ISGs) that restrict viral replication at various steps in viral life cycle [1, 2] . These known ISGs that suppress viral replication include APOBEC3s [3, 4] , SAMHD1 [5, 6] , and tetherin [7, 8] .
Among these ISGs, SAMHD1 (sterile alpha motif and HD domain-containing protein 1) was proposed to restrict the replication of retroviruses such as HIV-1 by depleting the intracellular dNTP pool required for viral replication. However, this restricting function toward HIV-1 is limited to noncycling cells [9] , while in cycling cells, this antiviral activity of SAMHD1 was lost due to its phosphorylation [10] . For HIV-1 restriction, whether mutating the phosphorylation sites of SAMHD1 affects its antiviral function dependent on its dNTPase activity remains controversial. Tang et al. had demonstrated that the phosphomimetic mutation T592E decreased SAMHD1's dNTPase activity employing crystallization and structure analysis in vitro [11] . However, it has also been reported that phosphorylation at T592 does not affect SAMHD1 dNTPase Abbreviations Co-IP, co-immunoprecipitation; DMEM, Dulbecco's modified Eagle's medium; GE, genome equivalents; HA, hemagglutinin; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; IFN, interferon; ISGs, IFN-stimulated genes; pgRNA, pregenomic RNA; PI, propidium iodide; PTMs, post-translational modifications; RIPA, radioimmunoprecipitation assay; siRNAs, small interfering RNAs. activity [10, 12] . In cycling cells, cyclin-dependent kinases 1, 2 and 6 (CDK1, CDK2, or CDK6) have been shown to regulate the phosphorylation of SAMHD1 directly or indirectly, and also HIV-1 replication, in different cell model [13] [14] [15] .
Hepatitis B virus (HBV) is the prototype member of the Hepadnavirus family. HBV specifically infects hepatocytes and causes development of liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC) [16] . Although HBV is a partially double-stranded DNA virus, its replication occurs via the reverse transcription of the viral pregenomic RNA (pgRNA) that is catalyzed by HBV polymerase [17] . In addition to suppressing HIV-1 replication, SAMHD1 has also been reported to restrict HBV replication [18] , and phosphorylation of SAMHD1 abrogated its inhibition of HBV [19] ; however, which CDKs are involved and how they participate in regulating phosphorylation of SAMHD1 during HBV infection is unclear. Here, we demonstrated that cyclin E2-CDK2 had a greater role in regulating phosphorylation of SAMHD1 than CDK1 or CDK6, and this phosphorylation abrogated SAMHD1's ability to restrict HBV replication in hepatoma cells.
Materials and methods

Plasmids employed
pCH9/3091 is an HBV expression vector that contains 1.1 copies of the HBV (genotype D) genome. The recombinant expression vector for hemagglutinin (HA)-tagged human SAMHD1 was purchased from Sino Biological Company. The human CDK2 and cyclin E2 coding sequences were cloned with an N-terminal Flag-tag in pReceiver vector by Genecopoeia Company. The SAMHD1-HA mutants were constructed by PCR-based mutagenesis. All the plasmid constructs were verified by DNA sequencing and protein expression was confirmed by western blot analysis in Huh7 cells.
Cell culture and transfection
Human hepatoma cells lines Huh7, HepG2.2.15, HepAD38 and human embryonic kidney 293T cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum as described before [20] . HepG2.2.15 were cultured in the presence of 500 µgÁmL À1 G418 to maintain the stably transfected HBV genome. HepAD38 cell was maintained as described previously [21] . All transfections were performed using Lipofectamine 3000 transfection reagent (Invitrogen, Carlsbad, CA, USA).
Chemical inhibitors and siRNA
The chemical inhibitors of CDK1 (RO-3306) and CDK6 (Palbociclib HCl) were purchased from Selleckchem (houston, TX, USA), and the CDK2 inhibitor II (SC-221409) was purchased from Santa Cruz (Dallas, TX, USA). All these compounds were dissolved in DMSO and stored at À20°C until employed.
Small interfering RNAs (siRNAs) were purchased from Shanghai Jima Company (Shanghai, China). The siRNA sequences targeting human SAMHD1, CDK1, CDK2, CDK6, Cyclin E, and cyclin A are in Table 1 . Cells were transfected with specific or nonspecific control siRNAs at concentration of 50 pmol by Lipofectamine 3000 (Invitrogen) according the manufacturer's protocol.
Virus production and HBV infection
Hepatitis B virus particle collection and infection with HepG2-NTCP cells were conducted as described before [20] . Briefly, HepG2-NTCP cells were inoculated with concentrated HBV viral particles derived from supernatants of HepAD38 cells at 1000 genome equivalents (GE) per cell in the medium containing 5% PEG 8000 for 16 h, then the virus was removed from the infected cells and the cells were maintained in Williams' E media before harvest.
Immunoprecipitation and western blotting
For co-immunoprecipitation (Co-IP) assay, 293T or Huh7 cells were transfected with indicated plasmids and lysed in radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40) containing protease inhibitors cocktail (Roche, Mannheim, Germany) and 1 mM PMSF for 30 min on ice. Cell lysates were incubated with different primary antibodies overnight at 4°C, then the immune complexes were pulled down with immobilized protein G agarose , Merck Company, Darmstadt, Germany) for 2 h at 4°C. Finally, the samples were resolved by 12.5% SDS/PAGE, and the membranes were immunoblotted employing the corresponding 
Isolation of viral DNA and southern blotting
Hepatitis B virus core-associated DNAs were purified and subjected to Southern blot analysis as previously described [22, 23] . Briefly, the core-associated DNA was collected through a sucrose density gradient and purified by phenol/ chloroform. The isolated viral DNA was electrophoresed onto 1.2% agarose gel, followed by denaturation and transfer onto a positively charged nylon membrane. The viral DNA was detected by using the DIG high prime DNA labeling and detection starter kit (Roche Diagnostics GmbH). qPCR for measuring HBV core-associated DNA was conducted as previously described [21, 22] .
Native gel analysis of HBV intracellular capsids
For detecting HBV core capsids, cell lysates were centrifuged at 13 000 g for 10 min, then the supernatants were run on a native 1% agarose gel, transferred onto a nitrocellulose filters in TNE buffer, and probe with an anticore antibody (B0586, Dako) as described before [24] .
Flow cytometry analysis
Cells were synchronized by starvation with 1% FBS for 72 h first, then transfected with indicated siRNA and restimulated with 10% FBS. The cells were then fixed with 70% alcohol at -20°C overnight, and stained with 50 lgÁmL À1 of propidium iodide (PI) for 30 min before applied for flow cytometry assay (CytoFLEX, Beckman Coulter Biotechnology, Suzhou, China).
Statistical analysis
Data were plotted and statistically analyzed using GRAPH-PAD PRISM5.0 (GraphPad Software, San Diego, CA, USA). A t-test was used to compare the statistical relevance of the two groups. For groups of three or more, analysis of variance (one-way ANOVA) with a Tukey post hoc test was performed. Data were normally presented as mean AE one standard deviation. A P value of ≤0.05 was considered as statistically significant.
Results
Restriction of HBV by SAMHD1 is negatively regulated by its phosphorylation at T592
SAMHD1 phosphorylation at T592 has been reported to affect its ability to restrict HIV-1 replication [10] . In order to investigate the impact of T592 phosphorylation on SAMHD1 restriction of HBV in hepatoma cells, we first measured the inhibition of HBV replication by SAMHD1 by cotransfecting HA-tagged SAMHD1 mutants together with HBV replicationcompetent plasmids in Huh7 cells (Fig. 1 ). Overexpression of different SAMHD1 mutants was confirmed by western blot using an anti-HA antibody; all of these mutant proteins were expressed at comparable levels except for Q548A/T592V, which accumulated to very low levels ( Fig. 1A , bottom). HBV core-associated DNA levels in the cytoplasm were detected by Southern blot or qPCR. Wild-type SAMDH1 and its T592V mutant that cannot be phosphorylated both still inhibited HBV replication, while this antiviral function was lost for the dNTPase-deficient D207N and D137N mutants and the phosphomimetic mutant T592E in Huh7 cells (Fig. 1A) , which was in accordance with previous reports [19] . These results suggested that the dNTPase activity and an unphosphorylated state of SAMHD1 are both essential for restricting HBV replication. In addition to dNTPase activity, the RNase activity of SAMHD1 was also suggested to be required for HIV-1 restriction [25] . However, in our experiments, the RNase activity is not required for SAMHD1 inhibition as double mutant Q548A/T592V still inhibited HBV replication similarly to the wildtype enzyme. Next, we asked whether other phosphorylation sites on SAMHD1 [10] could potentially affect its restriction of HBV replication. Plasmids encoding SAMHD1 wild-type and phosphomimetic mutants at residues 18, 21, 25, 33, 93, or 592 were cotranfected with HBV replication-competent plasmids into Huh7 cells. As shown in Fig. 1 , these phosphomimetic mutant proteins, including S18E, T21E, T25E, S33E, and S93E, all mutants except T592E still reduced HBV replication as well as the wild-type enzyme, and none of them affected HBV core protein expression (Fig. 1B . Therefore, we conclude that phosphorylation at T592, but not at other phosphorylation sites of SAMDH1, negatively affects its restriction of HBV replication in hepatocarcinoma cells.
Reducing levels of CDK2 but not CDK1 or CDK6 decreased SAMHD1 phosphorylation and HBV replication
It is unclear which CDKs participate in regulating phosphorylation of SAMHD1 and, hence, viral replication during HBV infection. Therefore, we investigated which CDKs are involved in this process in hepatocarcinoma cells. Firstly, we employed specific siRNA to knock down the candidate CDKs in Huh7 cells. Western blots revealed that protein expression of CDK1, CDK2, or CDK6 was reduced by >70% ( Fig. 2A, bottom) . Meanwhile, flow cytometry assay analysis of propidium iodide-labeled cells confirmed that these knockdown cells were at S/G 2 phase or G 1 phase, respectively, when knockdown CDK1, CDK2, or CDK6 (Fig. 2B) . Then, the phosphorylation of SAMHD1 and core-associated HBV DNA accumulation levels were measured by western blot and Southern blot. As shown in Fig. 2 , the amounts of core-associated HBV DNA in Huh7 cells were significantly decreased by 52% (P = 0.0049) after transfection with siRNAs against CDK2 (siCDK2 #387). Meanwhile, phosphorylation levels of SAMHD1 were also significantly decreased in the CDK2 knockdown cells. However, silencing of CDK1 or CDK6 expression had a slightly effect on reducing viral DNA or phosphorylation levels of SAMHD1 ( Fig. 2A) .
In addition, we tested the effect of knocking down the CDKs employing HepAD38 cells, as HepAD38 cells are tetracycline-regulated, stably transfected HepG2 cells in which HBV replication is induced by removal of tetracycline from the medium. Tetracycline was withdrawn in the culture of HepAD38 cells to initiate HBV replication, then the cells were transfected with CDK-specific siRNA to knock down the expression of CDK1, CDK2, and CDK6. Similar to the Huh7 experiment, knockdown of endogenous CDK2 led to a decreased viral DNA levels by 48% of the control (Fig. 2E) . A small decrease was observed with siRNA suppression of CDK1 or CDK6, but these alterations did not reach statistical significance. Again, silencing of CDK1, CDK2, or CDK6 reduced phosphorylation levels of SAMHD1 by 35%, 70%, and 21%, demonstrating an important role of CDK2 in regulating both SAMHD1 phosphorylation and HBV replication.
A CDK2 inhibitor blocked SAMHD1 phosphorylation and HBV replication
To confirm the role of CDK2 in regulation of SAMHD1 phosphorylation and HBV replication in hepatoma cells, we next employed highly specific inhibitor of CDK1 (RO-3306), CDK2 (CDK2 inhibitor II), and CDK6 (Palbociclib HCl). We first tested effects of CDK2 inhibitor II on viral DNA levels and phosphorylation of endogenous SAMHD1: the Huh7 cells were pretreated with CDK2 inhibitor II at subtoxic concentrations (Fig. 3A) and then were transfected with the HBV replication-competent plasmid. After transfection, the cells were treated with CDK2 inhibitor II every other day. Phosphorylation of SAMHD1 and HBV core-associated DNA levels in the cytoplasm were measured for additional 3 days as described above. As shown in Fig. S1 , CDK2 inhibitor II only reduced by 17% for viral DNA levels and 13% for phosphorylation of SAMHD1 at concentration of 5 lM; however, in the presence of exogenous SAMHD1 expression, CDK2 inhibitor II reduced the phosphorylation of SAMHD1 45% without affecting the CDK2 expression (Fig. 3B, bottom) . Consequently, core-associated HBV DNA levels were also decreased in a dose-dependent manner and reached about 94% at 5 lM in the presence of the CDK2 specific inhibitor II (Fig. 3B, upper) . This reduction was not due to cell toxicity as the 50% cytotoxic concentration (CC50) value of CDK2 inhibitor II in Huh7 cells is > 50 lM (Fig. 3A) . To test whether the reduced viral DNA levels derived from phosphorylation of SAMHD1 by CDK2, endogenous SAMHD1 was first knocked down by transfection of Huh7 cells with specific siRNAs, and then the cells were treated with CDK2 inhibitor II. The knockdown efficiency of SAMHD1 was confirmed by western blot (Fig. 3C) . The viral DNA levels were enhanced by about 2.5 fold when SAMHD1 was knocked down (Fig. 3C , compare lane 1 and 2), consistent with the antiviral function of endogenous SAMHD1 observed previously [18] . However, viral DNA levels were not reduced when cells were treated with CDK2 inhibitor II at 5.0 lM (Fig. 3D, compare lane 2 to 6 ). This indicated that the effects on HBV restriction by the CDK2 inhibitor were dependent on SAMHD1 phosphorylation. Similarly, treatment of HepG2.2.15 cells that constitutively express HBV from an integrated transgene with CDK2 inhibitor II leads to a decrease of phosphorylation of SAMHD1 and intracellular HBV DNA in a dosedependent manner, without affecting on CDK2 expression (Fig. S2) .
Next, RO-3306 or Palbociclib HCl, highly selectively inhibitors for CDK1 or CDK4/6 activity, respectively, was selected to test whether the inhibition of CDK1 or CDK6 activity would affect SAMHD1 phosphorylation and HBV DNA levels. Similarly, RO-3306 or Palbociclib HCl was treated with Huh7 cells in the presence of exogenous HBV and SAMHD1 expression at subtoxic concentrations (Fig. 4A) . The treatment of RO-3306 (5 lM) or Palbociclib HCl (2.5 lM) induced Huh7 cells arrested at S/G2 phase or G1 phase, respectively. However, neither of these compounds caused significant differences in SAMHD1 phosphorylation or in the levels of intracellular viral DNA (Fig. 4) . Therefore, combining these data with the knockdown experiments employing specific siRNAs in Fig. 2 , we conclude that CDK2 has a larger contribution in regulating phosphorylation of SAMHD1, and subsequently suppressing HBV replication, than CDK1 or CDK6, CDK2.
Interaction between CDK2 and SAMHD1
Next, to test whether CDK2 is physically associated with SAMHD1 in hepatoma cells, we conducted CDK2 and SAMHD1 Co-IP assays. Briefly, the Huh7 cells cotransfected with HA-tagged SAMHD1 and Flag-tagged CDK2 plasmids were lysed and immunoprecipitated with HA antibody, then the IP products were probed with an anti-FLAG antibody to detect exogenous Flag-tagged CDK2. Western blots revealed CDK2 in the samples immunoprecipitated with anti-HA antibody (Fig. 5A ). This indicated overexpressed SAMHD1 interacts with CDK2 in hepatocarcinoma cells, either directly or indirectly. To test whether endogenous SAMHD1 interacts with CDK2 under these conditions, the Huh7 cells were pretreated with 1000 UÁmL À1 of IFNa for 24 h to induce SAMHD1 expression, and then the cells were transfected with the Flag-tagged CDK2 expression plasmid. Again, the cell lyses were immunoprecipitated with Flag antibody and the IP products were probed with anti-SAMHD1 antibody. The SAMHD1/CDK2 protein interaction was increased with IFNatreatment compared with control (Fig. 5B , compare lane 1 and 2), while no band was observed in the IgG-negative control group as expected. CDK2 has been shown to physically associate with the HBV core protein [26] , so we next asked whether the interaction between SAMHD1 and CDK2 required involvement of the HBV core protein. 293T cells were employed for this Co-IP experiment to achieve better transfection efficiency and hence boost sensitivity. Similar to our previous experiments, 293T cells were cotransfected with HBV replication plasmids plus HA-tagged SAMDH1 and/or Flag-tagged CDK2 plasmids and then immunoprecipitated with anti-HBV core antibody to pull down the HBV core protein or capsids, with rabbit IgG as negative control. The IP products were probed with an anti-HA antibody or anti-Flag to detect the interaction with SAMHD1/core protein or CDK2/core protein. As expected, HBV core protein coimmunoprecipitated with CDK2, but not with SAMHD1 (Fig. 5C ), suggesting the interaction of . Effect of CDK1 inhibitor or CDK6 inhibitor on viral DNA and SAMHD1 phosphorylation in the presence of exogenous expression of SAMHD1. Viral DNA levels and phosphorylation of SAMHD1 were analyzed as described in Figure 3 . Statistical significance was determined by one-way ANOVA with Tukey post hoc test (*P < 0.05, **P < 0.01).
CDK2 and SAMHD1 does not require the HBV core protein.
Cyclin E2 is involved in regulating HBV replication that is dependent on the CDK-SAMHD1 interaction
Cyclin E or cyclin A had been reported to bind to and activate CDK2 during the cell cycle transition from G 1 to S phase or in the S phase, respectively [27] . Therefore, we investigated whether cyclin E or cyclin A involved regulation of SAMHD1 phosphorylation and HBV DNA levels. Cyclin E (including cyclin E1 and cyclin E2) or cyclin A was knocked down by transfection of specific siRNAs into Huh7 cells, and the suppression of protein levels was measured by western blot (Fig. 6) . The viral DNA levels or phosphorylation of SAMHD1 was not changed in the cyclin A knockdown cells (Fig. 6B) . Phosphorylation of SAMHD1 was significantly decreased by 65% in cells in which cyclin E2 was knocked down, but there was only a minor decrease in SAMHD1 phosphorylation in the cyclin E1 knockdown cells. Meanwhile, transfection of cyclin E2-specific siRNAs reduced HBV core-associated DNA levels by 42% (Fig. 6A, upper) compared to control siRNA-transfected cells. This suggests that cyclin E2, but not cyclin A had a substantial contribution to regulating HBV replication dependent on CDK2/SAMHD1 phosphorylation. Finally, we evaluated the effects of knocking down cyclin E in an HBV infection system. HepG2-NTCP cells were transfected with cyclin E1-or E2-specific siRNAs, and were then infected with HBV at 1000 genome equivalents (GE) per cell. Western analyses revealed the expected knockdown of endogenous cyclins E1 and E2. Knockdown of cyclin E2 led to decreased viral DNA levels after 6 days infection by 31.4%, while knockdown of cyclin E1 had no apparent effect (Fig. 6C) . Meanwhile, phosphorylation of SAMHD1 was also decreased by 49% in the cyclin E2 knockdown group. These data demonstrate that endogenous cyclin E2 may participate in regulating CDK2/SAMHD1 phosphorylation, consequently and subsequently HBV replication in hepatoma cells.
Discussion
Interferon has been employed for treatment of chronic hepatitis B for many years [28] , and its antiviral activity is mediated by an array of ISGs. Among these ISGs, SAMHD1 can restrict viral replication by depleting the cellular dNTP pool required for viral replication [18] . In addition, post-translational modifications (PTMs), especially phosphorylation of SAMHD1 have also been reported to negatively regulate its restriction of viral replication, although it is still a matter of debate that whether or not this phosphorylation that affects its antiviral activity is dependent on SAMHD1's dNTPase activity [10, 11, 13] . Here, we tested the effect of phosphorylation at multiple sites on SAMHD1 on its suppression of HBV replication. Mutation of the potential phosphorylation sites of SAMHD1 indicated that only the phosphomimetic T592E mutant, and not other variants (S18E, T21E, T25E, S33E, and S93E), abrogated its repression of HBV replication (Fig. 1B) . Meanwhile, SAMHD1 lost its anti-HBV function when its dNTPase active site was mutated (D207N and D137N) (Fig. 1A) , which is in accordance with a previous report [18] . This indicated that in addition to its dNTPase activity, blocking HBV replication by SAMHD1 was also regulated by phosphorylation at T592. However, whether this is a synergistic effect or not needs further clarification. Recently, it was reported that the dNTPase activity of SAMHD1 was enhanced by its acetylation at K405
[29], therefore, post-translational modifications of SAMHD1 seem to have multiple important roles in regulating its antiviral function. In cycling cells, SAMHD1 lost its antiviral function due to its phosphorylation. CDK1 has been identified as being responsible for SAMHD1 phosphorylation in proliferating U937 cells [10] , while CDK6-dependent CDK2 was also suggested to be associated with SAMHD1 phosphorylation in primary T cells and macrophages cells [14] . These discordant results may be derived from different cell models. Here, we sought to identify the potential candidate CDKs which are responsible for phosphorylation of SAMHD1 and HBV replication during cell cycle. Phosphorylation of SAMHD1 and viral DNA levels were both significantly reduced by knockdown of the endogenously expressed of CDK2, compared the minimal effects observed in the CDK1 or CDK6 knockdown groups. This suggested that CDK2 made a larger contribution in regulating phosphorylation of SAMHD1 and consequently viral replication. In agreement with this, CDK2 inhibitor II, not CDK1 or CDK6 inhibitors, effectively decreased phosphorylation levels of SAMHD1 in a dose-dependent manner in the presence of exogenous SAMHD1. Correspondingly, viral DNA levels were also inhibited by CDK2 inhibitor treatment (Fig. 3) . Importantly, CDK2 inhibitor II lost its effect on HBV replication when endogenous SAMHD1 expression was knocked down, strengthening the association between CDK2/SAMHD1 phosphorylation and HBV replication in hepatocarcinoma cells. Next, we demonstrated that CDK2 can interact with SAMHD1 endogenously or exogenously in hepatoma cells using a Co-IP approach (Fig. 5 ). CDK2 has a dual cytoplasmic and nuclear distribution [30] , and can be incorporated into HBV capsids [26] ; however, the CDK2/SAMHD1 interaction appears to occur in nucleus as CDK2, not SAMHD1, can be pulled down by the viral capsid (Fig. 5C) . Finally, HBV replication has been linked to cell cycle progression [31] , that is HBV can cause hepatocytes cells in the G0 phase to exit G0 but stall at the G1/S bounder [32] . Meanwhile, cyclin E or cyclin A can bind to and activate CDK2 during the cell cycle from G1 to S phase or in the S phase; therefore, it is possible that cyclin E or cyclin A would participate in this process of CDK2/SAMHD1 phosphorylation. Knockdown of the endogenous cyclin E or cyclin A expression demonstrated the important function of cyclin E2 in regulating the CDK2/SAMHD1 phosphorylation pathway (Fig. 6) . HBx was reported to interact with cyclin E/A -CDK2 and potentiate CDK2 activity during cell cycle [33] . Therefore, our data support the hypothesis that, during cell transition from G1 to S, HBV would recruit cyclin E2 to bind CDK2, which can phosphorylate SAMHD1; as a consequence, SAMHD1 lost its antiviral function and contributed to viral replication (Fig. S3) .
In conclusion, we report that as a host restriction factor, SAMHD1 phosphorylation is controlled by cyclin E2-CDK2 during HBV replication employing both HBV transfection and infection systems. Suppressing CDK2 expression or inhibiting its kinase activity can decrease phosphorylation levels of SAMHD1 and, as a consequence, viral replication is blocked. 
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Additional supporting information may be found online in the Supporting Information section at the end of the article. Fig. S1 . CDK2 Inhibitor II slightly blocks SAMHD1 phosphorylation and inhibits HBV replication in Huh7 cells. Fig. S2 . CDK2 Inhibitor II blocks SAMHD1 phosphorylation and inhibits HBV replication in HepG2.2.15 cells in the presence of exogenous SAMHD1. Fig. S3 . Proposed model for how HBV recruits cyclin E2-CDK2 to regulate SAMHD1 phosphorylation during the cell cycle.
